Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: PrEP Considerations in Cisgender Women

Source: Key Decisions in HIV Care
In this on-demand recording of a live webinar, expert faculty review key considerations for the use of PrEP in cisgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.
Latesha Elopre, MD, MSPH
Karine Lacombe, MD, PhD
Released: March 24, 2022

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including:

  • Discussion of the PrEP gap and racial and gender disparities in PrEP access
  • CDC, EACS, and WHO guidance on PrEP eligibility
  • PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir
  • Data from phase III trials on the efficacy of FTC/TDF daily for women including Partners PrEP, TDF, VOICE, and FEM-PrEP
  • Pharmacokinetic data of FTC/TDF and FTC/TAF in the female genital tract and discussion of why on-demand dosing of FTC/TDF is not recommended in cisgender women
  • Data and recommendations for the use of the dapivirine ring from ASPIRE and The Ring Study and their open-label extensions, DREAM and HOPE
  • Data from the HPTN084 study on the use of long-acting cabotegravir as PrEP for cisgender women
  • Recommendations for the use of PrEP during pregnancy and breastfeeding
  • Clinical monitoring and considerations during PrEP use

Information on this Educational Activity

Faculty

Latesha Elopre, MD, MSPH

Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama

Latesha Elopre, MD, MSPH, has disclosed that she has received funds for research support from Merck.
Karine Lacombe, MD, PhD

Professor
UMR-S1136
Sorbonne University
Professor
Head, Infectious Diseases Department
St Antoine Hospital, AP-HP
Paris, France

Karine Lacombe, MD, PhD, has disclosed that she has received consulting fees from Gilead Sciences, GlaxoSmithKline, Janssen, and MSD.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

Dr Kenric Ware discusses considerations for ongoing PrEP candidacy and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 20, 2023

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Slides on HIV ART management in complex clinical situations, including extensive previous treatment, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Released: January 11, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings